

WEST Search History

[Hide Items](#)[Restore](#)[Clear](#)[Cancel](#)

DATE: Tuesday, March 20, 2007

Hide?	Set Name	Query	Hit Count
<i>DB=PGPB,USPT,EPAB,JPAB,DWPI; PLUR=YES; OP=OR</i>			
<input type="checkbox"/>	L4	L1 and (Walker or Ripmeester or Zeng).in.	4
<input type="checkbox"/>	L3	l2 and protein\$4	9
<input type="checkbox"/>	L2	L1 same (freez\$4 or antifree\$4)	57
<input type="checkbox"/>	L1	clathrat\$4 same hydrat\$4	1211

END OF SEARCH HISTORY

=> d his full

(FILE 'HOME' ENTERED AT 13:04:59 ON 20 MAR 2007)

INDEX 'ADISCTI, ADISINSIGHT, ADISNEWS, AGRICOLA, ANABSTR, ANTE, AQUALINE, AQUASCI, BIOENG, BIOSIS, BIOTECHABS, BIOTECHDS, BIOTECHNO, CABA, CAPLUS, CEABA-VTB, CIN, CONFSCI, CROPB, CROPU, DDFB, DDFU, DGENE, DISSABS, DRUGB, DRUGMONOG2, DRUGU, EMBAL, EMBASE, ...' ENTERED AT 13:05:22 ON 20 MAR 2007

SEA (CLATHRAT?(S)HYDRAT?) OR (GAS?(S)HYDRATE?)

4 FILE ADISCTI
3 FILE ADISINSIGHT
11 FILE ADISNEWS
54 FILE AGRICOLA
103 FILE ANABSTR
129 FILE ANTE
45 FILE AQUALINE
804 FILE AQUASCI
57 FILE BIOENG
375 FILE BIOSIS
67 FILE BIOTECHABS
67 FILE BIOTECHDS
82 FILE BIOTECHNO
180 FILE CABA
9387 FILE CAPLUS
483 FILE CEABA-VTB
70 FILE CIN
481 FILE CONFSCI
2 FILE CROPB
4 FILE CROPU
64 FILE DDFB
79 FILE DDFU
110 FILE DGENE
282 FILE DISSABS
64 FILE DRUGB
180 FILE DRUGU
7 FILE EMBAL
343 FILE EMBASE
418 FILE ESBIODBASE
37 FILE FROSTI
63 FILE FSTA
694 FILE GENBANK
17 FILE HEALSAFE
2074 FILE IFIPAT
1123 FILE JICST-EPLUS
2 FILE KOSMET
140 FILE LIFESCI
304 FILE MEDLINE
656 FILE NTIS
400 FILE OCEAN
2601 FILE PASCAL
1 FILE PHAR
2 FILE PHARMAML
5 FILE PHIN
728 FILE PROMT
54 FILE RDISCLOSURE
3212 FILE SCISEARCH
913 FILE TOXCENTER
11086 FILE USPATFULL
1308 FILE USPAT2
11 FILE VETB
24 FILE VETU
123 FILE WATER
4473 FILE WPIDS
31 FILE WPIFV
4473 FILE WPINDEX
31 FILE IPA
358 FILE NLDB

L1 QUE (CLATHRAT?(S) HYDRAT?) OR (GAS?(S) HYDRATE?)

 D RANK

FILE 'USPATFULL, CAPLUS, WPIDS, SCISEARCH, PASCAL, IFIPAT, USPAT2,
JICST-EPLUS, TOXCENTER, AQUASCI, PROMT, ESBIODASE, OCEAN, BIOSIS, NLDB,
EMBASE, MEDLINE' ENTERED AT 13:11:48 ON 20 MAR 2007

L2 39907 SEA (CLATHRAT?(S) HYDRAT?) OR (GAS?(S) HYDRATE?)

L3 941 SEA L2 (S)(FREEZ? OR ANTIFREE?)

L4 34 SEA L3 (S)(PROTEI? OR POLYPEPT?)

L5 129 SEA L3 AND (PROTEI? OR POLYPEPT?)

L6 105 DUP REM L5 (24 DUPLICATES REMOVED)

 D TI L6 1-105

 D IBIB ABS L6 1 5 11-14 17 25 39 40 47 73 86 87 93

 D KWIC L6 87 73 40 13 1 17

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:sssptal652dmr

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * Welcome to STN International * * * * *

NEWS 1 Web Page URLs for STN Seminar Schedule - N. America
NEWS 2 "Ask CAS" for self-help around the clock
NEWS 3 DEC 18 CA/CAPplus pre-1967 chemical substance index entries enhanced
with preparation role
NEWS 4 DEC 18 CA/CAPplus patent kind codes updated
NEWS 5 DEC 18 MARPAT to CA/CAPplus accession number crossover limit increased
to 50,000
NEWS 6 DEC 18 MEDLINE updated in preparation for 2007 reload
NEWS 7 DEC 27 CA/CAPplus enhanced with more pre-1907 records
NEWS 8 JAN 08 CHEMLIST enhanced with New Zealand Inventory of Chemicals
NEWS 9 JAN 16 CA/CAPplus Company Name Thesaurus enhanced and reloaded
NEWS 10 JAN 16 IPC version 2007.01 thesaurus available on STN
NEWS 11 JAN 16 WPIDS/WPINDEX/WPIX enhanced with IPC 8 reclassification data
NEWS 12 JAN 22 CA/CAPplus updated with revised CAS roles
NEWS 13 JAN 22 CA/CAPplus enhanced with patent applications from India
NEWS 14 JAN 29 PHAR reloaded with new search and display fields
NEWS 15 JAN 29 CAS Registry Number crossover limit increased to 300,000 in
multiple databases
NEWS 16 FEB 15 PATDPASPC enhanced with Drug Approval numbers
NEWS 17 FEB 15 RUSSIAPAT enhanced with pre-1994 records
NEWS 18 FEB 23 KOREAPAT enhanced with IPC 8 features and functionality
NEWS 19 FEB 26 MEDLINE reloaded with enhancements
NEWS 20 FEB 26 EMBASE enhanced with Clinical Trial Number field
NEWS 21 FEB 26 TOXCENTER enhanced with reloaded MEDLINE
NEWS 22 FEB 26 IFICDB/IFIPAT/IFIUDB reloaded with enhancements
NEWS 23 FEB 26 CAS Registry Number crossover limit increased from 10,000
to 300,000 in multiple databases
NEWS 24 MAR 15 WPIDS/WPIX enhanced with new FRAGHITSTR display format
NEWS 25 MAR 16 CASREACT coverage extended
NEWS 26 MAR 20 MARPAT now updated daily

NEWS EXPRESS NOVEMBER 10 CURRENT WINDOWS VERSION IS V8.01c, CURRENT
MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP),
AND CURRENT DISCOVER FILE IS DATED 25 SEPTEMBER 2006.

NEWS HOURS STN Operating Hours Plus Help Desk Availability
NEWS LOGIN Welcome Banner and News Items
NEWS IPC8 For general information regarding STN implementation of IPC 8
NEWS X25 X.25 communication option no longer available

Enter NEWS followed by the item number or name to see news on that
specific topic.

All use of STN is subject to the provisions of the STN Customer
agreement. Please note that this agreement limits use to scientific
research. Use for software development or design or implementation
of commercial gateways or other similar uses is prohibited and may
result in loss of user privileges and other penalties.

* * * * * STN Columbus * * * * *

FILE 'HOME' ENTERED AT 13:04:59 ON 20 MAR 2007

=> index bioscience medicine

FILE 'DRUGMONOG' ACCESS NOT AUTHORIZED

COST IN U.S. DOLLARS

SINCE FILE	TOTAL
ENTRY	SESSION
0.21	0.21

FULL ESTIMATED COST

INDEX 'ADISCTI, ADISINSIGHT, ADISNEWS, AGRICOLA, ANABSTR, ANTE, AQUALINE, AQUASCI, BIOENG, BIOSIS, BIOTECHABS, BIOTECHDS, BIOTECHNO, CABA, CAPLUS, CEABA-VTB, CIN, CONFSCI, CROPB, CROPU, DDFB, DDFU, DGENE, DISSABS, DRUGB, DRUGMONOG2, DRUGU, EMBAL, EMBASE, ...' ENTERED AT 13:05:22 ON 20 MAR 2007

71 FILES IN THE FILE LIST IN STNINDEX

Enter SET DETAIL ON to see search term postings or to view search error messages that display as 0* with SET DETAIL OFF.

=> s (clathrat?(s)hydrat?) or (gas?(s)hydrate?)

- 4 FILE ADISCTI
- 3 FILE ADISINSIGHT
- 11 FILE ADISNEWS
- 54 FILE AGRICOLA
- 103 FILE ANABSTR
- 129 FILE ANTE
- 45 FILE AQUALINE
- 804 FILE AQUASCI
- 57 FILE BIOENG
- 375 FILE BIOSIS
- 67 FILE BIOTECHABS
- 67 FILE BIOTECHDS
- 82 FILE BIOTECHNO
- 180 FILE CABA
- 9387 FILE CAPLUS
- 483 FILE CEABA-VTB

16 FILES SEARCHED...

- 70 FILE CIN
- 481 FILE CONFSCI
- 2 FILE CROPB
- 4 FILE CROPU
- 64 FILE DDFB
- 79 FILE DDFU
- 110 FILE DGENE
- 282 FILE DISSABS
- 64 FILE DRUGB
- 180 FILE DRUGU
- 7 FILE EMBAL
- 343 FILE EMBASE
- 418 FILE ESBIODBASE

31 FILES SEARCHED...

- 37 FILE FROSTI
- 63 FILE FSTA
- 694 FILE GENBANK
- 17 FILE HEALSAFE
- 2074 FILE IFIPAT
- 1123 FILE JICST-EPLUS
- 2 FILE KOSMET
- 140 FILE LIFESCI
- 304 FILE MEDLINE
- 656 FILE NTIS

46 FILES SEARCHED...

- 400 FILE OCEAN
- 2601 FILE PASCAL

1 FILE PHAR
 2 FILE PHARMAML
 5 FILE PHIN
 728 FILE PROMT
 54 FILE RDISCLOSURE
 3212 FILE SCISEARCH
 913 FILE TOXCENTER
 11086 FILE USPATFULL
 61 FILES SEARCHED...
 1308 FILE USPAT2
 11 FILE VETB
 24 FILE VETU
 123 FILE WATER
 4473 FILE WPIDS
 31 FILE WPIFV
 4473 FILE WPINDEX
 31 FILE IPA
 358 FILE NLDB

58 FILES HAVE ONE OR MORE ANSWERS, 71 FILES SEARCHED IN STNINDEX

L1 QUE (CLATHRAT?(S) HYDRAT?) OR (GAS?(S) HYDRATE?)

=> d rank

F1	11086	USPATFULL
F2	9387	CAPLUS
F3	4473	WPIDS
F4	4473	WPINDEX
F5	3212	SCISEARCH
F6	2601	PASCAL
F7	2074	IFIPAT
F8	1308	USPAT2
F9	1123	JICST-EPLUS
F10	913	TOXCENTER
F11	804	AQUASCI
F12	728	PROMT
F13	694	GENBANK
F14	656	NTIS
F15	483	CEABA-VTB
F16	481	CONFSCI
F17	418	ESBIOBASE
F18	400	OCEAN
F19	375	BIOSIS
F20	358	NLDB
F21	343	EMBASE
F22	304	MEDLINE
F23	282	DISSABS
F24	180	CABA
F25	180	DRUGU
F26	140	LIFESCI
F27	129	ANTE
F28	123	WATER
F29	110	DGENE
F30	103	ANABSTR
F31	82	BIOTECHNO
F32	79	DDFU
F33	70	CIN
F34	67	BIOTECHABS
F35	67	BIOTECHDS
F36	64	DDFB
F37	64	DRUGB
F38	63	FSTA
F39	57	BIOENG
F40	54	AGRICOLA
F41	54	RDISCLOSURE

F42	45	AQUALINE
F43	37	FROSTI
F44	31	WPIFV
F45	31	IPA
F46	24	VETU
F47	17	HEALSAFE
F48	11	ADISNEWS
F49	11	VETB
F50	7	EMBAL
F51	5	PHIN
F52	4	ADISCTI
F53	4	CROPU
F54	3	ADISINSIGHT
F55	2	CROPB
F56	2	KOSMET
F57	2	PHARMAML
F58	1	PHAR

=> file f1-f12, f17-f22

COST IN U.S. DOLLARS

SINCE FILE

ENTRY

TOTAL

SESSION

FULL ESTIMATED COST

6.93

7.14

FILE 'USPATFULL' ENTERED AT 13:11:48 ON 20 MAR 2007
CA INDEXING COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'CAPLUS' ENTERED AT 13:11:48 ON 20 MAR 2007
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'WPIDS' ENTERED AT 13:11:48 ON 20 MAR 2007
COPYRIGHT (C) 2007 THE THOMSON CORPORATION

FILE 'WPINDEX' ACCESS NOT AUTHORIZED

FILE 'SCISEARCH' ENTERED AT 13:11:48 ON 20 MAR 2007
Copyright (c) 2007 The Thomson Corporation

FILE 'PASCAL' ENTERED AT 13:11:48 ON 20 MAR 2007
Any reproduction or dissemination in part or in full,
by means of any process and on any support whatsoever
is prohibited without the prior written agreement of INIST-CNRS.
COPYRIGHT (C) 2007 INIST-CNRS. All rights reserved.

FILE 'IFIPAT' ENTERED AT 13:11:48 ON 20 MAR 2007
COPYRIGHT (C) 2007 IFI CLAIMS(R) Patent Services (IFI)

FILE 'USPAT2' ENTERED AT 13:11:48 ON 20 MAR 2007
CA INDEXING COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'JICST-EPLUS' ENTERED AT 13:11:48 ON 20 MAR 2007
COPYRIGHT (C) 2007 Japan Science and Technology Agency (JST)

FILE 'TOXCENTER' ENTERED AT 13:11:48 ON 20 MAR 2007
COPYRIGHT (C) 2007 ACS

FILE 'AQUASCI' ENTERED AT 13:11:48 ON 20 MAR 2007
COPYRIGHT 2007 FAO (On behalf of the ASFA Advisory Board). All rights reserved.

FILE 'PROMT' ENTERED AT 13:11:48 ON 20 MAR 2007
COPYRIGHT (C) 2007 Gale Group. All rights reserved.

FILE 'ESBIOBASE' ENTERED AT 13:11:48 ON 20 MAR 2007

COPYRIGHT (C) 2007 Elsevier Science B.V., Amsterdam. All rights reserved.

FILE 'OCEAN' ENTERED AT 13:11:48 ON 20 MAR 2007

COPYRIGHT (C) 2007 Cambridge Scientific Abstracts (CSA)

FILE 'BIOSIS' ENTERED AT 13:11:48 ON 20 MAR 2007

Copyright (c) 2007 The Thomson Corporation

FILE 'NLDB' ENTERED AT 13:11:48 ON 20 MAR 2007

COPYRIGHT (C) 2007 Gale Group. All rights reserved.

FILE 'EMBASE' ENTERED AT 13:11:48 ON 20 MAR 2007

Copyright (c) 2007 Elsevier B.V. All rights reserved.

FILE 'MEDLINE' ENTERED AT 13:11:48 ON 20 MAR 2007

=> s (clathrat?(s)hydrat?) or (gas?(s)hydrate?)

12 FILES SEARCHED...

L2 39907 (CLATHRAT?(S) HYDRAT?) OR (GAS?(S) HYDRATE?)

=> s 12 (s)(freez? or antifree?)

L3 941 L2 (S)(FREEZ? OR ANTIFREE?)

=> s 13 (s)(protei? or polypept?)

12 FILES SEARCHED...

L4 34 L3 (S)(PROTEI? OR POLYPEPT?)

=> s 13 and (protei? or polypept?)

L5 129 L3 AND (PROTEI? OR POLYPEPT?)

=> dup rem 15

PROCESSING COMPLETED FOR L5

L6 105 DUP REM L5 (24 DUPLICATES REMOVED)

=> d ti 16 1-105

L6 ANSWER 1 OF 105 USPATFULL on STN

TI Environmentally benign anti-icing or deicing fluids

L6 ANSWER 2 OF 105 USPATFULL on STN

TI Barrier units and articles made therefrom

L6 ANSWER 3 OF 105 USPATFULL on STN

TI Liposome loading with metal ions

L6 ANSWER 4 OF 105 USPATFULL on STN

TI Powder formation by atmospheric spray-freeze drying

L6 ANSWER 5 OF 105 USPATFULL on STN

TI Shale Inhibition additive for oil/gas down hole fluids and methods for making and using same

L6 ANSWER 6 OF 105 USPATFULL on STN

TI Freeze-drying microscope stage apparatus and process of using the same

L6 ANSWER 7 OF 105 USPATFULL on STN

TI Deep water completions fracturing fluid compositions

L6 ANSWER 8 OF 105 USPATFULL on STN

TI Liposomal formulations comprising dihydrosphingomyelin and methods of use thereof

L6 ANSWER 9 OF 105 WPIDS COPYRIGHT 2007

THE THOMSON CORP on STN

TI Wound dressing composition, useful to deliver wound healing agents (e.g. alpha-1-antichymotrypsin) for the treatment of e.g. neuropathic ulcers, diabetic ulcers and infected wounds, comprises a cellulose ether and a gellan gum

L6 ANSWER 10 OF 105 WPIDS COPYRIGHT 2007 THE THOMSON CORP on STN

TI Identifying therapeutically active antibodies for cancer or autoimmune disorder therapy, comprises formulating a multivalent antibody construct, measuring therapeutic activity, and comparing activity of construct to antibodies in free form

L6 ANSWER 11 OF 105 CAPLUS COPYRIGHT 2007 ACS on STN DUPLICATE 1

TI Effect of antifreeze protein on nucleation, growth and memory of gas hydrates

L6 ANSWER 12 OF 105 CAPLUS COPYRIGHT 2007 ACS on STN DUPLICATE 2

TI Effect of Antifreeze Proteins on the Nucleation, Growth, and the Memory Effect during Tetrahydrofuran Clathrate Hydrate Formation

L6 ANSWER 13 OF 105 USPATFULL on STN DUPLICATE 3

TI Environmentally benign anti-icing or deicing fluids

L6 ANSWER 14 OF 105 USPATFULL on STN DUPLICATE 4

TI Antifreeze proteins for inhibition of clathrate hydrate formation and reformation

L6 ANSWER 15 OF 105 USPATFULL on STN DUPLICATE 5

TI Powder formation by atmospheric spray-freeze drying

L6 ANSWER 16 OF 105 USPATFULL on STN DUPLICATE 6

TI Ultrasound imaging and treatment

L6 ANSWER 17 OF 105 USPATFULL on STN DUPLICATE 7

TI Well drilling method and drilling fluid

L6 ANSWER 18 OF 105 USPATFULL on STN

TI Methods of preparing gaseous precursor-filled microspheres

L6 ANSWER 19 OF 105 USPATFULL on STN

TI Methods and compositions using immunomodulatory compounds for the treatment and management of central nervous system disorders or diseases

L6 ANSWER 20 OF 105 USPATFULL on STN

TI Lipid carrier compositions with enhanced blood stability

L6 ANSWER 21 OF 105 USPATFULL on STN

TI Cell penetrating therapeutic agents

L6 ANSWER 22 OF 105 USPATFULL on STN

TI Novel targeted compositions for diagnostic and therapeutic use

L6 ANSWER 23 OF 105 WPIDS COPYRIGHT 2007 THE THOMSON CORP on STN

TI Cementitious composition, useful as water reducing agents for modifying hydratable cementitious materials, comprises a hydratable cementitious binder and a composition comprising a lignosulfonic acid, a gluconic acid and a xylonic acid

L6 ANSWER 24 OF 105 CAPLUS COPYRIGHT 2007 ACS on STN

TI Water structuring in phase transitions and in chemical reactions at sulfur sites in proteins

L6 ANSWER 25 OF 105 CAPLUS COPYRIGHT 2007 ACS on STN

TI	Inhibition of clathrate hydrates by antifreeze proteins	
L6	ANSWER 26 OF 105	USPATFULL on STN DUPLICATE 8
TI	Liposomal phosphodiester, phosphorothioate, and p-ethoxy oligonucleotides	
L6	ANSWER 27 OF 105	USPATFULL on STN
TI	Non-invasive intravascular thrombolysis using modified ultrasound techniques	
L6	ANSWER 28 OF 105	USPATFULL on STN
TI	Expandable gastric retention device	
L6	ANSWER 29 OF 105	USPATFULL on STN
TI	Cationic lipids and use thereof	
L6	ANSWER 30 OF 105	USPATFULL on STN
TI	Methods of using and compositions comprising selective cytokine inhibitory drugs for the treatment and management of disorders of the central nervous system	
L6	ANSWER 31 OF 105	USPATFULL on STN
TI	Methods and compositions for blood pool identification, drug distribution quantification and drug release verification	
L6	ANSWER 32 OF 105	USPATFULL on STN
TI	Desalination of ocean water	
L6	ANSWER 33 OF 105	USPATFULL on STN
TI	Multi-test assembly for evaluating, detecting and monitoring processes at elevated pressure	
L6	ANSWER 34 OF 105	USPATFULL on STN DUPLICATE 9
TI	Comonomer compositions for production of imide-containing polyamino acids	
L6	ANSWER 35 OF 105	USPATFULL on STN DUPLICATE 10
TI	Comonomer compositions for production of imide-containing polyamino acids	
L6	ANSWER 36 OF 105	USPATFULL on STN DUPLICATE 11
TI	Comonomer compositions for production of imide-containing polyamino acids	
L6	ANSWER 37 OF 105	USPATFULL on STN DUPLICATE 12
TI	NON-INVASIVE METHODS FOR SURGERY IN THE VASCULATURE	
L6	ANSWER 38 OF 105	USPATFULL on STN DUPLICATE 13
TI	Novel therapeutic delivery systems	
L6	ANSWER 39 OF 105	CAPLUS COPYRIGHT 2007 ACS on STN DUPLICATE 14
TI	Use of antifreeze proteins for inhibition of clathrate hydrate formation and reformation	
L6	ANSWER 40 OF 105	USPATFULL on STN
TI	Environmentally benign anti-icing or deicing fluids	
L6	ANSWER 41 OF 105	USPATFULL on STN
TI	Novel methods of imaging and treatment with targeted compositions	
L6	ANSWER 42 OF 105	USPATFULL on STN
TI	Lipid carrier compositions with enhanced blood stability	
L6	ANSWER 43 OF 105	USPATFULL on STN
TI	Deep water completions fracturing fluid compositions	

L6 ANSWER 44 OF 105 USPATFULL on STN
TI Liposome loading with metal ions

L6 ANSWER 45 OF 105 USPATFULL on STN
TI Methods of preparing gaseous precursor-filled microspheres

L6 ANSWER 46 OF 105 USPATFULL on STN
TI Methods of imaging and treatment with targeted compositions

L6 ANSWER 47 OF 105 CAPLUS COPYRIGHT 2007 ACS on STN DUPLICATE 15
TI The inhibition of tetrahydrofuran clathrate-hydrate formation with antifreeze protein

L6 ANSWER 48 OF 105 USPATFULL on STN DUPLICATE 16
TI Comonomer compositions for production of imide-containing polyamino acids

L6 ANSWER 49 OF 105 USPATFULL on STN
TI Novel targeted compositions for diagnostic and therapeutic use

L6 ANSWER 50 OF 105 USPATFULL on STN
TI Ultrasound imaging and treatment

L6 ANSWER 51 OF 105 USPATFULL on STN
TI Method of preparing gas and gaseous precursor-filled microspheres

L6 ANSWER 52 OF 105 USPATFULL on STN
TI Starch-containing lubricant systems for oil field applications

L6 ANSWER 53 OF 105 USPATFULL on STN
TI Method of magnetic resonance focused surgical and therapeutic ultrasound

L6 ANSWER 54 OF 105 USPATFULL on STN
TI Amines useful in inhibiting gas hydrate formation

L6 ANSWER 55 OF 105 USPATFULL on STN
TI Therapeutic delivery systems

L6 ANSWER 56 OF 105 USPATFULL on STN
TI Silicon amphiphilic compounds and the use thereof

L6 ANSWER 57 OF 105 USPATFULL on STN
TI Blast resistant and blast directing assemblies

L6 ANSWER 58 OF 105 USPATFULL on STN
TI Hydrogel compositions for controlled delivery of virus vectors and methods of use thereof

L6 ANSWER 59 OF 105 USPATFULL on STN
TI Gas filled microspheres as magnetic resonance imaging contrast agents

L6 ANSWER 60 OF 105 USPATFULL on STN
TI Dehydration plant

L6 ANSWER 61 OF 105 USPATFULL on STN
TI Methods for ultrasound imaging involving the use of a contrast agent and multiple images and processing of same

L6 ANSWER 62 OF 105 USPATFULL on STN
TI Liposome-assisted synthesis of polymeric nanoparticles

L6 ANSWER 63 OF 105 USPATFULL on STN
TI Lipid-modified insulin incorporated liposomes for selectively delivering cytotoxic agents to hepatoma cells

L6 ANSWER 64 OF 105 USPATFULL on STN
TI Targeted contrast agents for diagnostic and therapeutic use

L6 ANSWER 65 OF 105 USPATFULL on STN
TI Method of computed tomography using fluorinated gas-filled lipid microspheres as contrast agents

L6 ANSWER 66 OF 105 USPATFULL on STN
TI Method of magnetic resonance focused surgical and therapeutic ultrasound

L6 ANSWER 67 OF 105 USPATFULL on STN
TI Targeted gas and gaseous precursor-filled liposomes

L6 ANSWER 68 OF 105 USPATFULL on STN
TI Liposomal phosphodiester, phosphorothioate, and p-ethoxy oligonucleotides

L6 ANSWER 69 OF 105 CAPLUS COPYRIGHT 2007 ACS on STN DUPLICATE 17
TI Liposome comprising a polypeptide in which peptide antigens obtained from different virus origins are linked consecutively

L6 ANSWER 70 OF 105 USPATFULL on STN
TI Frozen ultrasonic gas suspensions

L6 ANSWER 71 OF 105 USPATFULL on STN
TI Methods of preparing gas-filled liposomes

L6 ANSWER 72 OF 105 USPATFULL on STN
TI Gaseous precursor filled microspheres as magnetic resonance imaging contrast agents

L6 ANSWER 73 OF 105 USPATFULL on STN
TI Method for inhibiting the plugging of conduits by gas hydrates

L6 ANSWER 74 OF 105 USPATFULL on STN
TI Methods of computed tomography using perfluorocarbon gaseous filled microspheres as contrast agents

L6 ANSWER 75 OF 105 USPATFULL on STN
TI Liposomal phosphodiester, phosphorothioate, and P-ethoxy oligonucleotides

L6 ANSWER 76 OF 105 USPATFULL on STN
TI Methods of preparing gas and gaseous precursor-filled microspheres

L6 ANSWER 77 OF 105 USPATFULL on STN
TI Method of storing frozen microbubble suspensions

L6 ANSWER 78 OF 105 USPATFULL on STN
TI Method of echographic imaging using frozen gasbubble suspensions

L6 ANSWER 79 OF 105 USPATFULL on STN
TI Polyethylene glycol modified ceramide lipids and liposome uses thereof

L6 ANSWER 80 OF 105 USPATFULL on STN
TI Compositions for the introduction of polyanionic materials into cells

L6 ANSWER 81 OF 105 USPATFULL on STN
TI Therapeutic drug delivery systems

L6 ANSWER 82 OF 105 USPATFULL on STN
TI Compositions for the introduction of polyanionic materials into cells

L6 ANSWER 83 OF 105 USPATFULL on STN

TI Gas and gaseous precursor filled microspheres as topical and subcutaneous delivery vehicles

L6 ANSWER 84 OF 105 USPATFULL on STN

TI Method of producing high-molecular products from collagen-containing materials, and product produced by the same

L6 ANSWER 85 OF 105 USPATFULL on STN

TI Methods of preparing gas-filled liposomes

L6 ANSWER 86 OF 105 EMBASE COPYRIGHT (c) 2007 Elsevier B.V. All rights reserved on STN

TI Freeze-dried biomolecules: FT-ICR studies of the specific solvation of functional groups and clathrate formation observed by the slow evaporation of water from hydrated peptides and model compounds in the gas phase.

L6 ANSWER 87 OF 105 USPATFULL on STN

TI Method for inhibiting the plugging of conduits by gas hydrates

L6 ANSWER 88 OF 105 USPATFULL on STN

TI Method of preparing gas and gaseous precursor-filled microspheres

L6 ANSWER 89 OF 105 USPATFULL on STN

TI Therapeutic drug delivery systems

L6 ANSWER 90 OF 105 USPATFULL on STN

TI Therapeutic delivery systems related applications

L6 ANSWER 91 OF 105 SCISEARCH COPYRIGHT (c) 2007 The Thomson Corporation on STN DUPLICATE 18

TI Anhydrobiosis and cold tolerance in tardigrades

L6 ANSWER 92 OF 105 USPATFULL on STN

TI Methods of preparing gas-filled liposomes

L6 ANSWER 93 OF 105 USPATFULL on STN

TI Method for inhibiting the plugging of conduits by gas hydrates

L6 ANSWER 94 OF 105 USPATFULL on STN

TI Use of hydrate formation to control membrane mimetic systems

L6 ANSWER 95 OF 105 USPATFULL on STN

TI Composition for targeting, storing and loading of liposomes

L6 ANSWER 96 OF 105 USPATFULL on STN

TI Freeze dry composition and method for oral administration of drugs, biologicals, nutrients and foodstuffs

L6 ANSWER 97 OF 105 USPATFULL on STN

TI Inclusion complexes of cyclodextrins by agglomeration

L6 ANSWER 98 OF 105 USPATFULL on STN

TI Novel composition for targeting, storing and loading of liposomes

L6 ANSWER 99 OF 105 USPATFULL on STN

TI Efficient method for preparation of prolonged release liposome-based drug delivery system

L6 ANSWER 100 OF 105 WPIDS COPYRIGHT 2007 THE THOMSON CORP on STN

TI Frozen confectionery prods. - comprising a mixture of water, sweetener, flavour, and nitrous oxide gas hydrate clathrate

L6 ANSWER 101 OF 105 USPATFULL on STN

TI Composition for targeting, storing and loading of liposomes

L6 ANSWER 102 OF 105 USPATFULL on STN

TI Use of hydrates for aqueous solution treatment

L6 ANSWER 103 OF 105 USPATFULL on STN

TI Foraminous mat products

L6 ANSWER 104 OF 105 USPATFULL on STN

TI Controlled humidity freeze drying process

L6 ANSWER 105 OF 105 USPATFULL on STN

TI Soybean process

=> d ibib abs 16 1 5 11-14 17 25 39 40 47 73 86 87 93

L6 ANSWER 1 OF 105 USPATFULL on STN

ACCESSION NUMBER: 2007:15189 USPATFULL

TITLE: Environmentally benign anti-icing or deicing fluids

INVENTOR(S): Sapienza, Richard, Shoreham, NY, UNITED STATES
Johnson, Axel, North Babylon, NY, UNITED STATES
Ricks, William, Westerville, OH, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2007012896	A1	20070118
APPLICATION INFO.:	US 2006-522690	A1	20060918 (11)
RELATED APPLN. INFO.:	Continuation of Ser. No. US 2005-103753, filed on 12 Apr 2005, GRANTED, Pat. No. US 7138071		
	Continuation-in-part of Ser. No. US 2000-675495, filed on 29 Sep 2000, GRANTED, Pat. No. US 6506318		
	Continuation-in-part of Ser. No. US 1999-436811, filed on 9 Nov 1999, GRANTED, Pat. No. US 6129857		
	Continuation of Ser. No. US 1998-161865, filed on 28 Sep 1998, GRANTED, Pat. No. US 5980774		
	Continuation-in-part of Ser. No. US 1997-940936, filed on 30 Sep 1997, GRANTED, Pat. No. US 5876621		
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	APPLICATION		
LEGAL REPRESENTATIVE:	HEDMAN & COSTIGAN P.C., 1185 AVENUE OF THE AMERICAS, NEW YORK, NY, 10036, US		
NUMBER OF CLAIMS:	5		
EXEMPLARY CLAIM:	1-45		
LINE COUNT:	968		
CAS INDEXING IS AVAILABLE FOR THIS PATENT.			
AB	Deicing compositions comprised of hydroxyl-containing organic compounds and/or organic acid salts are disclosed.		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 5 OF 105 USPATFULL on STN

ACCESSION NUMBER: 2006:137717 USPATFULL

TITLE: Shale Inhibition additive for oil/gas down hole fluids and methods for making and using same

INVENTOR(S): Kippie, David P., San Antonio, TX, UNITED STATES
Gatlin, Larry W., San Antonio, TX, UNITED STATES

PATENT ASSIGNEE(S): CLEARWATER INTERNATIONAL, L.L.C. (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2006116296	A1	20060601
APPLICATION INFO.:	US 2004-999796	A1	20041129 (10)
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	APPLICATION		

LEGAL REPRESENTATIVE: ROBERT W STROZIER, P.L.L.C, PO BOX 429, BELLAIRE, TX,
77402-0429, US

NUMBER OF CLAIMS: 62

EXEMPLARY CLAIM: 1

LINE COUNT: 3087

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB An under-balanced drilling fluid additive is disclosed which reduces reactive shale and/or clay swelling during under-balanced drilling operations, where the additive includes an effective amount of a choline salt. A method for under-balanced drilling is also disclosed including the step of circulating a drilling fluid including an effective amount of a choline salt to reduce reactive shale and/or clay swelling during under-balanced drilling operations.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 11 OF 105 CAPLUS COPYRIGHT 2007 ACS on STN DUPLICATE 1

ACCESSION NUMBER: 2006:887124 CAPLUS

DOCUMENT NUMBER: 145:232759

TITLE: Effect of antifreeze protein on nucleation, growth and memory of gas hydrates

AUTHOR(S): Zeng, Huang; Moudrakovski, Igor L.; Ripmeester, John A.; Walker, Virginia K.

CORPORATE SOURCE: Steacie Institute for Molecular Sciences, National Research Council of Canada, Ottawa, ON, K1A 0R6, Can.

SOURCE: AIChE Journal (2006), 52(9), 3304-3309

CODEN: AICEAC; ISSN: 0001-1541

PUBLISHER: John Wiley & Sons, Inc.

DOCUMENT TYPE: Journal

LANGUAGE: English

AB The effect of Type I antifreeze protein (AFP) from winter flounder on the formation of propane hydrate and methane hydrate was studied. We show that the formation of both hydrates is inhibited significantly, with both nucleation and crystal growth being affected. Also, AFP showed the so-far unique ability to eliminate the "memory effect" in the reformation of gas hydrate. We have proposed a mechanism involving the interference of AFP with heterogeneous nucleation and subsequent growth of the hydrates. A number of samples must be studied to obtain meaningful statistics, and that magnetic resonance imaging provides a novel way of studying the nucleation and growth of hydrate in multiple droplets.

REFERENCE COUNT: 22 THERE ARE 22 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 12 OF 105 CAPLUS COPYRIGHT 2007 ACS on STN DUPLICATE 2

ACCESSION NUMBER: 2006:130827 CAPLUS

DOCUMENT NUMBER: 144:228161

TITLE: Effect of Antifreeze Proteins on the Nucleation, Growth, and the Memory Effect during Tetrahydrofuran Clathrate Hydrate Formation

AUTHOR(S): Zeng, Huang; Wilson, Lee D.; Walker, Virginia K.; Ripmeester, John A.

CORPORATE SOURCE: Department of Biology, Queen's University, Kingston, ON, K7L 3N6, Can.

SOURCE: Journal of the American Chemical Society (2006), 128(9), 2844-2850

CODEN: JACSAT; ISSN: 0002-7863

PUBLISHER: American Chemical Society

DOCUMENT TYPE: Journal

LANGUAGE: English

AB The inhibition activities of two antifreeze proteins (AFPs) on the formation of THF (THF) clathrate hydrate have been tested. AFPs from fish (wfAFP) and insect (CfAFP) changed the

morphol. of growing THF hydrate crystals. Also, both AFPs showed higher activities in inhibiting the formation of THF hydrate than a com. kinetic inhibitor, poly(vinylpyrrolidone) (PVP). Strikingly, both AFPs also showed the ability to eliminate the "memory effect" in which the crystallization of hydrate occurs more quickly after the initial formation. This is the first report of mols. that can inhibit the memory effect. Since the homogeneous nucleation temperature for THF hydrate was measured to be 237 K, close to that observed for ice itself, the action of kinetic inhibitors must involve heterogeneous nucleation. On the basis of our results, we postulate a mechanism for heterogeneous nucleation, the memory effect and its elimination by antifreeze proteins.

REFERENCE COUNT: 22 THERE ARE 22 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 13 OF 105 USPATFULL on STN DUPLICATE 3
 ACCESSION NUMBER: 2005:206529 USPATFULL
 TITLE: Environmentally benign anti-icing or deicing fluids
 INVENTOR(S): Sapienza, Richard, Shoreham, NY, UNITED STATES
 Johnson, Axel, North Babylon, NY, UNITED STATES
 Ricks, William, Westerville, OH, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2005179000	A1	20050818
	US 7138071	B2	20061121
APPLICATION INFO.:	US 2005-103753	A1	20050412 (11)
RELATED APPLN. INFO.:	Continuation of Ser. No. US 2003-341540, filed on 13 Jan 2003, ABANDONED Continuation-in-part of Ser. No. US 2000-675495, filed on 29 Sep 2000, GRANTED, Pat. No. US 6506318 Continuation-in-part of Ser. No. US 1999-436811, filed on 9 Nov 1999, GRANTED, Pat. No. US 6129857 Continuation of Ser. No. US 1998-161865, filed on 28 Sep 1998, GRANTED, Pat. No. US 5980774 Continuation-in-part of Ser. No. US 1997-940936, filed on 30 Sep 1997, GRANTED, Pat. No. US 5876621		
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	APPLICATION		
LEGAL REPRESENTATIVE:	HEDMAN & COSTIGAN P.C., 1185 AVENUE OF THE AMERICAS, NEW YORK, NY, 10036, US		
NUMBER OF CLAIMS:	29		
EXEMPLARY CLAIM:	1-33		
LINE COUNT:	1032		
CAS INDEXING IS AVAILABLE FOR THIS PATENT.			
AB	Deicing compositions comprised of hydroxyl-containing organic compounds and/or organic acid salts are disclosed.		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 14 OF 105 USPATFULL on STN DUPLICATE 4
 ACCESSION NUMBER: 2005:186726 USPATFULL
 TITLE: Antifreeze proteins for inhibition of clathrate hydrate formation and reformation
 INVENTOR(S): Walker, Virginia K, Ontario, CANADA
 Ripmeester, John A, Ontario, CANADA
 Zeng, Huang, Ontario, CANADA

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2005161631	A1	20050728
APPLICATION INFO.:	US 2003-510557	A1	20030411 (10)
	WO 2003-CA528		20030411

NUMBER	DATE
--------	------

PRIORITY INFORMATION: US 2002-372522P 20020412 (60)
DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: LICATLA & TYRRELL P.C., 66 E. MAIN STREET, MARLTON, NJ,
08053, US
NUMBER OF CLAIMS: 20
EXEMPLARY CLAIM: 1
LINE COUNT: 896

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Antifreeze proteins, active fragments of these
antifreeze proteins and mimetics thereof for use in
inhibiting clathrate hydrate formation and
reformation and designing and selecting inhibitors of clathrate
hydrate formation and reformation are provided.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 17 OF 105 USPATFULL on STN DUPLICATE 7
ACCESSION NUMBER: 2005:96183 USPATFULL
TITLE: Well drilling method and drilling fluid
INVENTOR(S): Grainger, Neil, Cleveland, UNITED KINGDOM
Herzhaft, Benjamin, Suresnes, FRANCE
White, Mark, North Yorkshire, UNITED KINGDOM
Audibert Hayet, Annie, Croissy Sur Seine, FRANCE

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2005082090	A1	20050421
	US 7055628	B2	20060606
APPLICATION INFO.:	US 2003-493407	A1	20021014 (10)
	WO 2002-FR3497		20021014

	NUMBER	DATE
PRIORITY INFORMATION:	GB 2001-25685	20011026
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	Millen White Zelano & Branigan, Arlington Courthouse Plaza I, 2200 Clarendon Blvd, Suite 1400, Arlington, VA, 22201, US	
NUMBER OF CLAIMS:	17	
EXEMPLARY CLAIM:	1	
LINE COUNT:	903	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention relates to a well drilling method consisting in removing
the drilling cuttings using an aqueous drilling fluid such as a foam
including a foaming agent which is, or includes, at least one
mono-(aliphatic hydrocarbyl) phosphate ester. More specifically, the
drilling fluid takes the form of a potassium and/or alkanolamine and/or
alkylalkanolamine salt, said foam also comprising a foam stabiliser.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 25 OF 105 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2005:1161714 CAPLUS
DOCUMENT NUMBER: 144:391374
TITLE: Inhibition of clathrate hydrates
by antifreeze proteins
AUTHOR(S): Zeng, Huang
CORPORATE SOURCE: Queen's Univ., Kingston, ON, Can.
SOURCE: (2004) 150 pp. Avail.: UMI, Order No. DANR00011
From: Diss. Abstr. Int., B 2005, 66(2), 735
DOCUMENT TYPE: Dissertation
LANGUAGE: English

AB Unavailable

L6 ANSWER 39 OF 105 CAPLUS COPYRIGHT 2007 ACS on STN DUPLICATE 14

ACCESSION NUMBER: 2003:837353 CAPLUS

DOCUMENT NUMBER: 139:325775

TITLE: Use of antifreeze proteins for
inhibition of clathrate hydrate
formation and reformation

INVENTOR(S): Walker, Virginia K.; Ripmeester, John A.; Zeng, Huang

PATENT ASSIGNEE(S): Queen's University at Kingston, Can.

SOURCE: PCT Int. Appl., 35 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003087532	A1	20031023	WO 2003-CA528	20030411
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
CA 2496631	A1	20031023	CA 2003-2496631	20030411
AU 2003227152	A1	20031027	AU 2003-227152	20030411
US 2005161631	A1	20050728	US 2003-510557	20030411
PRIORITY APPLN. INFO.:			US 2002-372522P	P 20020412
			WO 2003-CA528	W 20030411

AB Antifreeze proteins, active fragments of these
antifreeze proteins and mimetics thereof for use in
inhibiting clathrate hydrate formation and reformation
and designing and selecting inhibitors of clathrate
hydrate formation and reformation are provided.

REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 40 OF 105 USPATFULL on STN

ACCESSION NUMBER: 2003:242223 USPATFULL

TITLE: Environmentally benign anti-icing or deicing fluids

INVENTOR(S): Sapienza, Richard, Shoreham, NY, UNITED STATES

Johnson, Axel, North Babylon, NY, UNITED STATES

Ricks, William, Westerville, OH, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003168625	A1	20030911
APPLICATION INFO.:	US 2003-341540	A1	20030113 (10)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 2000-675495, filed on 29 Sep 2000, GRANTED, Pat. No. US 6506318 Continuation-in-part of Ser. No. US 1999-436811, filed on 9 Nov 1999, GRANTED, Pat. No. US 6129857 Continuation of Ser. No. US 1998-161865, filed on 28 Sep 1998, GRANTED, Pat. No. US 5980774 Continuation-in-part of Ser. No. US 1997-940936, filed on 30 Sep 1997, GRANTED, Pat. No. US 5876621		
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	APPLICATION		
LEGAL REPRESENTATIVE:	Alan B. Clement, Esq., HEDMAN & COSTIGAN, P.C., 1185		

Avenue of the Americas, New York, NY, 10036
NUMBER OF CLAIMS: 45
EXEMPLARY CLAIM: 1
LINE COUNT: 1156
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Deicing compositions comprised of hydroxyl-containing organic compounds
and/or organic acid salts are disclosed.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 47 OF 105 CAPLUS COPYRIGHT 2007 ACS on STN DUPLICATE 15
ACCESSION NUMBER: 2003:489829 CAPLUS
DOCUMENT NUMBER: 139:247655
TITLE: The inhibition of tetrahydrofuran clathrate-
hydrate formation with antifreeze
protein
AUTHOR(S): Zeng, Huang; Wilson, Lee D.; Walker, Virginia K.;
Ripmeester, John A.
CORPORATE SOURCE: Steacie Institute for Molecular Sciences, National
Research Council, Ottawa, ON, K1A 0R6, Can.
SOURCE: Canadian Journal of Physics (2003), 81(1/2), 17-24
CODEN: CJPHAD; ISSN: 0008-4204
PUBLISHER: National Research Council of Canada
DOCUMENT TYPE: Journal
LANGUAGE: English
AB The effect of Type I fish antifreeze protein (AFP)
from the winter flounder, *Pleuronectes americanus* (Walbaum), (WfAFP) on
the formation of THF clathrate hydrate was studied by
observing changes in THF crystal morphol. and determining the induction time
for
nucleation. AFP retarded THF clathrate-hydrate growth at the tested
temps. and modified the THF clathrate hydrate crystal morphol. from
octahedral to plate-like. AFP appears to be even more effective than the
kinetic inhibitor, polyvinylpyrrolidone. Recombinant AFP from an insect,
a spruce budworm, *Choristoneura fumiferana*, moth, (Cf) was also tested for
inhibition activity by observation of the THF hydrate crystal-growth
habit. Like WfAFP, CfAFP appeared to show adsorption on multiple THF
hydrate crystal faces. A protein with no antifreeze
activity, cytochrome C, was used as a control and it neither changed the
morphol. of the THF clathrate-hydrate crystals, nor
retarded the formation of the hydrate. Preliminary expts. on
the inhibition activity of WfAFP on a natural gas hydrate assessed
induction time and the amount of propane gas consumed. Similar to the
observations for THF, the data indicated that WfAFP inhibited propane
hydrate growth. Taken together, these results support our hypothesis that
AFP can inhibit clathrate hydrate growth and as well, offer promise for
the understanding of the inhibition mechanism.
REFERENCE COUNT: 12 THERE ARE 12 CITED REFERENCES AVAILABLE FOR THIS
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 73 OF 105 USPATFULL on STN
ACCESSION NUMBER: 1999:30252 USPATFULL
TITLE: Method for inhibiting the plugging of conduits by gas
hydrates
INVENTOR(S): Klomp, Ulfert Cornelis, Amsterdam, Netherlands
Reijnhart, Rene, Amsterdam, Netherlands
PATENT ASSIGNEE(S): Shell Oil Company, Houston, TX, United States (U.S.
corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5879561		19990309
APPLICATION INFO.:	US 1996-636618		19960423 (8)

NUMBER	DATE
--------	------

PRIORITY INFORMATION: EP 1995-201067 19950425
DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Hruskoci, Peter A.
NUMBER OF CLAIMS: 18
EXEMPLARY CLAIM: 1
LINE COUNT: 509

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB A method for inhibiting the plugging of a conduit, the conduit containing a flowing mixture comprising an amount of hydrocarbons having from one to eight carbon atoms and an amount of water wherein the amounts of hydrocarbons and water could form hydrates at conduit temperatures and pressures, the method comprising the steps of:

adding to the mixture an amount of a hydrate formation inhibitor component of the formula ##STR1## wherein two of R.sub.1 -R.sub.4 are independently normal or branched alkyls having 4 or 5 carbon atoms,

two of R.sub.1 -R.sub.4 are independently representing organic moieties having at least 8 carbon atoms,

A represents a nitrogen or phosphorus atom, and

Y represents an anion;

the amount of the hydrate formation inhibitor component being effective to inhibit formation of hydrates in the mixture at conduit temperatures and pressures; and

flowing the mixture containing the hydrate formation inhibitor component through the conduit.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 86 OF 105 EMBASE COPYRIGHT (c) 2007 Elsevier B.V. All rights reserved on STN

ACCESSION NUMBER: 1998404674 EMBASE

TITLE: Freeze-dried biomolecules: FT-ICR studies of the specific solvation of functional groups and clathrate formation observed by the slow evaporation of water from hydrated peptides and model compounds in the gas phase.

AUTHOR: Lee S.-W.; Freivogel P.; Schindler T.; Beauchamp J.L.

CORPORATE SOURCE: J.L. Beauchamp, Beckman Institute, California Institute of Technology, Pasadena, CA 91125, United States

SOURCE: Journal of the American Chemical Society, (18 Nov 1998) Vol. 120, No. 45, pp. 11758-11765. .
ISSN: 0002-7863 CODEN: JACSAT

COUNTRY: United States

DOCUMENT TYPE: Journal; Article

FILE SEGMENT: 029 Clinical Biochemistry

LANGUAGE: English

SUMMARY LANGUAGE: English

ENTRY DATE: Entered STN: 10 Jan 1999

Last Updated on STN: 10 Jan 1999

AB Solvents evaporation from extensively hydrated peptides and selected model compounds formed by electrospray ionization has been examined using an external ion source Fourier transform ion cyclotron resonance (FT-ICR) mass spectrometer. Water evaporation from the clusters, formed at room temperature by appropriate operation of an electrospray ion source, is initially rapid and results in evaporative cooling of the clusters to a temperature around 130-150 K, determined by the balance between evaporative cooling and heating by background blackbody radiation. In this 'freeze-drying' process, it is observed that the kinetics of solvent

evaporation and the cluster size distributions are highly dependent on the nature of the core ion in the cluster. In agreement with earlier studies of the hydrated proton, pure water clusters exhibit special stability characteristic of clathrate formation where, for example, a hydronium ion is encapsulated by a pentagonal dodecahedron of twenty water molecules. Similar clustering of water occurs around protonated primary alkylamines where the protonated amine replaces one of the water molecules in the clathrate structures, which encapsulate one or more neutral water molecules. This observation supports the conjecture that the doubly protonated cyclic decapeptide gramicidin S with 40 water molecules attached, the most significant magic number observed in mass spectra at various delay times, has both protonated ornithine residues solvated by pentagonal dodecahedron clathrate structures. Other peptides such as doubly protonated bradykinin do not exhibit any specific solvation during the freeze-drying process. Studies of model compounds are presented which reveal other interesting aspects of water structure around singly and multiply charged ions with low extents of hydration, including the observation of neutral clathrates attached to a 'spectator' ion.

L6 ANSWER 87 OF 105 USPATFULL on STN
 ACCESSION NUMBER: 97:61902 USPATFULL
 TITLE: Method for inhibiting the plugging of conduits by gas hydrates
 INVENTOR(S): Klomp, Ulfert Cornelis, Amsterdam, Netherlands
 Kruka, Vitold Raimond, Houston, TX, United States
 Reijnhart, Rene, Amsterdam, Netherlands
 Weisenborn, Anton Jacobus, Amsterdam, Netherlands
 PATENT ASSIGNEE(S): Shell Oil Company, Houston, TX, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5648575		19970715
APPLICATION INFO.:	US 1995-370954		19950110 (8)
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	Granted		
PRIMARY EXAMINER:	Caldarola, Glenn A.		
ASSISTANT EXAMINER:	Wood, Elizabeth D.		
LEGAL REPRESENTATIVE:	Christensen, Del S.		
NUMBER OF CLAIMS:	28		
EXEMPLARY CLAIM:	1		
LINE COUNT:	713		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The plugging of conduits containing a mixture of low-boiling hydrocarbons and water is inhibited by adding to the mixture an effective amount of at least one alkylated compound of the general formula formula ##STR1## wherein R.sub.1 and R.sub.2 each are independently chosen from normal or branched alkyls containing a chain of at least 4 carbon atoms,

R.sub.5 is an organic moiety containing a chain of at least 4 atoms,

X is S, N--R.sub.4 or P--R.sub.4,

R.sub.4 is H or an organic substituent, suitably an alkyl or alkenyl group having from 8 to 20 carbon atoms, and

Y-- is an anion.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 93 OF 105 USPATFULL on STN
 ACCESSION NUMBER: 95:94597 USPATFULL
 TITLE: Method for inhibiting the plugging of conduits by gas hydrates

INVENTOR(S): Klomp, Ulfert C., Amsterdam, Netherlands
Kruka, Vitold R., Houston, TX, United States
Reijnhart, Rene, Amsterdam, Netherlands
Weisenborn, Anton J., Amsterdam, Netherlands
PATENT ASSIGNEE(S): Shell Oil Company, Houston, TX, United States (U.S.
corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5460728		19951024
APPLICATION INFO.:	US 1993-171544		19931221 (8)
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	Granted		
PRIMARY EXAMINER:	McCarthy, Neil		
NUMBER OF CLAIMS:	14		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	5 Drawing Figure(s); 1 Drawing Page(s)		
LINE COUNT:	608		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB A method is provided for inhibiting the formation of hydrates in streams containing low-boiling hydrocarbons and water. The method includes adding to the stream a component of the formula: ##STR1## wherein R.sub.1, R.sub.2, and R.sub.3 are independently chosen from the group consisting of normal and branched alkyls having at least 4 carbon atoms, and X is N--R.sub.4, wherein R.sub.4 is selected from the group consisting of hydrogen and organic substituents and

Y.sup.- is an anion. The amount added is an amount that is effective to inhibit formation of hydrates in the mixture at conduit temperatures and pressures. The preferred R.sub.4 is an alkyl or alkenyl having from eight to twenty carbons, and the preferred R.sub.1, R.sub.2, and R.sub.3 are alkyls having four to six carbon atoms.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

=> d kwic 16 87 73 40 13 1 17

L6 ANSWER 87 OF 105 USPATFULL on STN

SUMM It has been known for a long time, that gas hydrate crystals, when allowed to form and grow inside a conduit such as a pipeline, tend to block or even damage. . . possible in principle: removal of free water; maintaining elevated temperatures; and/or reduced pressures or the addition of melting point depressants (antifreezes). In practice, antifreezes are most frequently used. However, antifreezes, such as the lower alcohols and glycols, have to be added in substantial amounts to be effective, typically several tens of percent by weight of the water present. A disadvantage of such amounts is the cost of the antifreeze, and that recovery is relatively expensive.

SUMM Plants and poikilothermic animals such as insects and cold-water fish are known to protect themselves from freezing, both by antifreezes such as glycols and by special peptides and glycopeptides (termed antifreeze proteins and antifreeze glycoproteins) that interfere with ice crystal growth (A. L. de Vries, Comp. Blochem. Physiol, 73, 627 (1982)). The present applicants found such cold-water fish peptides and glycopeptides also to be effective in interfering with the growth of gas-hydrate crystals. However, their production and use for this purpose are currently considered to be uneconomical.

L6 ANSWER 73 OF 105 USPATFULL on STN

SUMM It has been known for a long time, that gas hydrate crystals, when allowed to form and grow inside a conduit such as a

pipeline, tend to block or even damage. . . possible in principle: removal of free water; maintaining elevated temperatures and/or reduced pressures or the addition of melting point depressants (antifreezes). In practice, antifreezes are most frequently used. However, antifreezes, such as the lower alcohols and glycols, have to be added in substantial amounts to be effective, typically several tens of percent by weight of the water present. A disadvantage of such amounts is the cost of the antifreeze. A further disadvantage is that recovery is relatively expensive.

SUMM Plants and poikilothermic animals such as insects and cold-water fish are known to protect themselves from freezing; both by antifreezes such as glycols and by special peptides and glycopeptides (termed antifreeze proteins and antifreeze glycoproteins) that interfere with ice crystal growth (A.L. de Vries, Comp. Biochem. Physiol, 73, 627 (1982)). Although we found such cold-water fish peptides and glycopeptides to be effective in interfering with the growth of gas-hydrate crystals, their production and use for this purpose are currently considered to be uneconomical.

L6 ANSWER 40 OF 105 USPATFULL on STN

SUMM [0028] In still further embodiments, the compositions of the present invention are useful to prevent freezing or de-freezing in a wide variety of other applications. An example is that the compositions of the present invention can be used in drilling fluids used to break-up (melt) frozen gas hydrates.

DETD . . . having the following approximate composition:

COMPONENT GROUPS	% BY WEIGHT	% ON DRY SUBSTANCE
Dissolved Solids (RDS)	74.84	--
Ash	22.81	30.47
Crude Protein	19.44	25.97
Nitrogen Compounds (As N)	3.11	4.16
α-Amino Nitrogen Compounds (As N)	0.41	0.55
INDIVIDUAL COMPOUNDS		
Sucrose	13.13	17.54
Raffinose	3.96	5.29
Invert	0.020	0.027
Betaine	8.95	
DETD . . . approx.		
Sucrose	26.5% on DS approx.	
Raffinose	5.0% on DS approx.	
Nitrogen Compound (as N)	3.5% on DS approx.	
Crude Protein	22.0% on DS approx.	
Betaine	8.5% on DS approx.	
Amino Acids	0.5% on DS approx.	
Ash	30.0% on DS approx.	

L6 ANSWER 13 OF 105 USPATFULL on STN

DUPLICATE 3

SUMM In still further embodiments, the compositions of the present invention are useful to prevent freezing or de-freezing in a wide variety of other applications. An example is that the compositions of the present invention can be used in drilling fluids used to break-up (melt) frozen gas hydrates.

DETD . . . the following approximate composition:

% BY

% ON DRY

	WEIGHT	SUBSTANCE
COMPONENT GROUPS		
Dissolved Solids (RDS)	74.84	--
Ash	22.81	30.47
Crude Protein	19.44	25.97
Nitrogen Compounds (As N)	3.11	4.16
α-Amino Nitrogen Compounds (As N) 0.41		0.55
INDIVIDUAL COMPOUNDS		
Sucrose	13.13	17.54
Raffinose	3.96	5.29
Invert	0.020	0.027
Betaine.		
DETD		approx.
Sucrose	26.5%	on DS approx.
Raffinose	5.0%	on DS approx.
Nitrogen Compound (as N)	3.5%	on DS approx.
Crude Protein	22.0%	on DS approx.
Betaine	8.5%	on DS approx.
Amino Acids	0.5%	on DS approx.
Ash	30.0%	on DS approx.

CLM What is claimed is:
 . . . claim 45 wherein said liquid comprises a fire extinguisher fluid, an engine radiator fluid, a heat transfer system fluid, a gas dehydration system fluid, a lavatory fluid, a drilling fluid, a fluid for break-up of gas hydrates or a fluid for freeze protection of plumbing lines.

L6 ANSWER 1 OF 105 USPATFULL on STN
 SUMM In still further embodiments, the compositions of the present invention are useful to prevent freezing or de-freezing in a wide variety of other applications. An example is that the compositions of the present invention can be used in drilling fluids used to break-up (melt) frozen gas hydrates.

DETD

	% ON DRY	% BY WEIGHT	SUBSTANCE
COMPONENT GROUPS			
Dissolved Solids (RDS)	74.84		--
Ash	22.81		30.47
Crude Protein	19.44		25.97
Nitrogen Compounds (As N)	3.11		4.16
α-Amino Nitrogen Compounds (As N) 0.41		0.55	
INDIVIDUAL COMPOUNDS			
Sucrose	13.13		17.54
Raffinose	3.96		5.29
Invert	0.020		0.027
Betaine	8.95.		
DETD			approx.
Sucrose	26.5%	on DS approx.	
Raffinose	5.0%	on DS approx.	
Nitrogen Compound (as N)	3.5%	on DS approx.	
Crude Protein	22.0%	on DS approx.	
Betaine	8.5%	on DS approx.	
Amino Acids	0.5%	on DS approx.	
Ash	30.0%	on DS approx.	

L6 ANSWER 17 OF 105 USPATFULL on STN

DUPLICATE 7

SUMM used in amounts of from 0 to 10%, usually 2 to 3% by weight of the drilling fluid; and gas hydrate inhibitors particularly for low temperature drilling, such as polyvinyl pyrrolidone and similar polymers, quaternary ammonium salts or anti-freeze fish proteins, typically used in amounts of from 0 to 20%, usually 2 to 5% by weight of the drilling fluid.

=>

=> d his full

(FILE 'HOME' ENTERED AT 13:04:59 ON 20 MAR 2007)

INDEX 'ADISCTI, ADISINSIGHT, ADISNEWS, AGRICOLA, ANABSTR, ANTE, AQUALINE, AQUASCI, BIOENG, BIOSIS, BIOTECHABS, BIOTECHDS, BIOTECHNO, CABA, CAPLUS, CEABA-VTB, CIN, CONFSCI, CROPB, CROPU, DDFB, DDFU, DGENE, DISSABS, DRUGB, DRUGMONOG2, DRUGU, EMBAL, EMBASE, ...' ENTERED AT 13:05:22 ON 20 MAR 2007
SEA (CLATHRAT?(S)HYDRAT?) OR (GAS?(S)HYDRATE?)

4 FILE ADISCTI
3 FILE ADISINSIGHT
11 FILE ADISNEWS
54 FILE AGRICOLA
103 FILE ANABSTR
129 FILE ANTE
45 FILE AQUALINE
804 FILE AQUASCI
57 FILE BIOENG
375 FILE BIOSIS
67 FILE BIOTECHABS
67 FILE BIOTECHDS
82 FILE BIOTECHNO
180 FILE CABA
9387 FILE CAPLUS
483 FILE CEABA-VTB
70 FILE CIN
481 FILE CONFSCI
2 FILE CROPB
4 FILE CROPU
64 FILE DDFB
79 FILE DDFU
110 FILE DGENE
282 FILE DISSABS
64 FILE DRUGB
180 FILE DRUGU
7 FILE EMBAL
343 FILE EMBASE
418 FILE ESBIODASE
37 FILE FROSTI
63 FILE FSTA
694 FILE GENBANK
17 FILE HEALSAFE
2074 FILE IFIPAT
1123 FILE JICST-EPLUS
2 FILE KOSMET
140 FILE LIFESCI
304 FILE MEDLINE
656 FILE NTIS
400 FILE OCEAN
2601 FILE PASCAL
1 FILE PHAR
2 FILE PHARMAML

5 FILE PHIN
 728 FILE PROMT
 54 FILE RDISCLOSURE
 3212 FILE SCISEARCH
 913 FILE TOXCENTER
 11086 FILE USPATFULL
 1308 FILE USPAT2
 11 FILE VETB
 24 FILE VETU
 123 FILE WATER
 4473 FILE WPIDS
 31 FILE WPIFV
 4473 FILE WPINDEX
 31 FILE IPA
 358 FILE NLDB

L1 QUE (CLATHRAT?(S) HYDRAT?) OR (GAS?(S) HYDRATE?)

 D RANK

FILE 'USPATFULL, CAPLUS, WPIDS, SCISEARCH, PASCAL, IFIPAT, USPAT2, JICST-EPLUS, TOXCENTER, AQUASCI, PROMT, ESBIOBASE, OCEAN, BIOSIS, NLDB, EMBASE, MEDLINE' ENTERED AT 13:11:48 ON 20 MAR 2007

L2 39907 SEA (CLATHRAT?(S) HYDRAT?) OR (GAS?(S) HYDRATE?)

L3 941 SEA L2 (S) (FREEZ? OR ANTIFREE?)

L4 34 SEA L3 (S) (PROTEI? OR POLYPEPT?)

L5 129 SEA L3 AND (PROTEI? OR POLYPEPT?)

L6 105 DUP REM L5 (24 DUPLICATES REMOVED)

D TI L6 1-105

D IBIB ABS L6 1 5 11-14 17 25 39 40 47 73 86 87 93

D KWIC L6 87 73 40 13 1 17

FILE HOME

FILE STNINDEX

FILE USPATFULL

FILE COVERS 1971 TO PATENT PUBLICATION DATE: 20 Mar 2007 (20070320/PD)

FILE LAST UPDATED: 20 Mar 2007 (20070320/ED)

HIGHEST GRANTED PATENT NUMBER: US7194769

HIGHEST APPLICATION PUBLICATION NUMBER: US2007061936

CA INDEXING IS CURRENT THROUGH 20 Mar 2007 (20070320/UPCA)

ISSUE CLASS FIELDS (/INCL) CURRENT THROUGH: 20 Mar 2007 (20070320/PD)

REVISED CLASS FIELDS (/NCL) LAST RELOADED: Oct 2006

USPTO MANUAL OF CLASSIFICATIONS THESAURUS ISSUE DATE: Oct 2006

FILE CAPLUS

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 20 Mar 2007 VOL 146 ISS 13

FILE LAST UPDATED: 19 Mar 2007 (20070319/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply. They are available for your review at: